NASDAQ:CMTA - Clementia Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$12.54 +0.38 (+3.13 %)
(As of 07/16/2018 03:07 AM ET)
Previous Close$12.54
Today's Range$11.8866 - $12.83
52-Week Range$11.13 - $20.15
Volume191,886 shs
Average Volume132,075 shs
Market Capitalization$397.74 million
P/E Ratio-1.58
Dividend YieldN/A
BetaN/A
Clementia Pharmaceuticals logoClementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial. Clementia Pharmaceuticals Inc. was founded in 2010 and is based in Montreal, Canada.

Receive CMTA News and Ratings via Email

Sign-up to receive the latest news and ratings for CMTA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CMTA
CUSIPN/A
Phone514-940-3600

Debt

Debt-to-Equity RatioN/A
Current Ratio7.06
Quick Ratio7.06

Price-To-Earnings

Trailing P/E Ratio-1.58
Forward P/E Ratio-7.08
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.47 per share
Price / Book2.81

Profitability

EPS (Most Recent Fiscal Year)($7.93)
Net Income$-115,450,000.00
Net MarginsN/A
Return on Equity-165.55%
Return on Assets-71.97%

Miscellaneous

Employees30
Outstanding Shares31,720,000
Market Cap$397.74

The Truth About Cryptocurrencies

Clementia Pharmaceuticals (NASDAQ:CMTA) Frequently Asked Questions

What is Clementia Pharmaceuticals' stock symbol?

Clementia Pharmaceuticals trades on the NASDAQ under the ticker symbol "CMTA."

How were Clementia Pharmaceuticals' earnings last quarter?

Clementia Pharmaceuticals Inc (NASDAQ:CMTA) released its quarterly earnings data on Wednesday, May, 9th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.33) by $0.09. View Clementia Pharmaceuticals' Earnings History.

When is Clementia Pharmaceuticals' next earnings date?

Clementia Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for Clementia Pharmaceuticals.

What price target have analysts set for CMTA?

5 Wall Street analysts have issued 12 month price targets for Clementia Pharmaceuticals' stock. Their predictions range from $23.00 to $32.00. On average, they anticipate Clementia Pharmaceuticals' stock price to reach $26.60 in the next year. This suggests a possible upside of 112.1% from the stock's current price. View Analyst Ratings for Clementia Pharmaceuticals.

What is the consensus analysts' recommendation for Clementia Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clementia Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Clementia Pharmaceuticals' key competitors?

Who are Clementia Pharmaceuticals' key executives?

Clementia Pharmaceuticals' management team includes the folowing people:
  • Dr. Clarissa Desjardins, Founder, Pres, CEO & Director (Age 51)
  • Mr. Michael Singer, CFO & Corp. Sec. (Age 53)
  • Dr. Donna Roy Grogan M.D., Chief Medical Officer (Age 61)
  • Mr. Jeffery Packman, Chief Devel. Officer (Age 51)
  • Mr. Eric Grinstead, Chief Commercial Officer (Age 61)

When did Clementia Pharmaceuticals IPO?

(CMTA) raised $101 million in an initial public offering on Wednesday, August 2nd 2017. The company issued 7,200,000 shares at $13.00-$15.00 per share. Morgan Stanley and Leerink Partners acted as the underwriters for the IPO and Wedbush Securities and BTIG were co-managers.

Has Clementia Pharmaceuticals been receiving favorable news coverage?

News coverage about CMTA stock has been trending positive on Monday, Accern Sentiment reports. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Clementia Pharmaceuticals earned a news impact score of 0.36 on Accern's scale. They also assigned press coverage about the company an impact score of 45.05 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

How do I buy shares of Clementia Pharmaceuticals?

Shares of CMTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Clementia Pharmaceuticals' stock price today?

One share of CMTA stock can currently be purchased for approximately $12.54.

How big of a company is Clementia Pharmaceuticals?

Clementia Pharmaceuticals has a market capitalization of $397.74 million. The company earns $-115,450,000.00 in net income (profit) each year or ($7.93) on an earnings per share basis. Clementia Pharmaceuticals employs 30 workers across the globe.

How can I contact Clementia Pharmaceuticals?

Clementia Pharmaceuticals' mailing address is 4150 ST CATHERINE STREET WEST SUITE 550, MONTREAL A8, H3Z 2Y5. The company can be reached via phone at 514-940-3600 or via email at [email protected]


MarketBeat Community Rating for Clementia Pharmaceuticals (NASDAQ CMTA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  100 (Vote Outperform)
Underperform Votes:  103 (Vote Underperform)
Total Votes:  203
MarketBeat's community ratings are surveys of what our community members think about Clementia Pharmaceuticals and other stocks. Vote "Outperform" if you believe CMTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CMTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.